Toxicity management in HCC treatment is discussed by medical experts.
The transcript is part of a medical expert discussion on the management of hepatocellular carcinoma (HCC) and its treatment strategies, focusing on the challenges of immunotherapy and the importance of education for both physicians and patients. The experts emphasize the need for vigilance as adverse events can occur unpredictably and stress the significance of recognizing early signs of potential complications, such as headaches and diarrhea. They discuss the importance of comprehensive patient support systems, including access to various specialists like ophthalmologists, rheumatologists, and dermatologists, as well as the role of nurse navigators and the implementation of referral systems to overcome barriers to care. The conversation highlights the complexity of managing treatment toxicities, especially in the context of the COVID era, where distinguishing between different symptoms can be challenging. The experts stress the significance of understanding the patient’s social background and support system, with a particular focus on optimizing care for vulnerable groups like the elderly or those with poor socioeconomic status. They emphasize the necessity of considering the individual patient’s quality of life and maintaining a patient-centered approach throughout the treatment process. The discussion underscores the importance of clinical pathways and the practical application of therapeutic approaches in real-world settings, addressing the gap between clinical trials and actual patient outcomes.
Overall, the conversation reflects the multidimensional nature of managing HCC, with a strong emphasis on patient education, comprehensive support systems, and a holistic understanding of the patient’s social and clinical context. The experts advocate for a personalized and proactive approach to managing treatment toxicities, ensuring optimal patient care and quality of life throughout the treatment journey.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More
EHA Plenary Abstracts Zoom in From Investigational Drugs to Molecular Signatures
June 14th 2025Abstracts presented during the plenary session of the 2025 European Hematology Association (EHA) Congress spanned from novel drug regimens for myeloma and lymphoma to investigation of leukemias on the molecular and genetic levels.
Read More
COVID-19 Deaths Cloud Interpretation of Acalabrutinib-Venetoclax Combo Results
June 13th 2025A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings in a cross-trial comparison were complicated by the inclusion of deaths related to COVID-19.
Read More
Measurable Residual Disease in Decision-Making: An Opportunity, but Not a Promise
June 13th 2025Skepticism still persists around the use of measurable residual disease (MRD) for clinical and regulatory decision-making in the European context, but panelists explained the next steps that are required to advance the use of MRD.
Read More
2 Commerce Drive
Cranbury, NJ 08512